August 4, 2014 Aug 01, 2025 Jul 10, 2025

Purchase price multiple rapidly declining on strength of business and synergy capture 12 $133 $201 2019PF 2022E 12 Clariant Color EBITDA Growth Purchase Price Multiple 10.8x 7.0x 6.4x 2019PF 2021 2022E w/ Full Synergies (1) (1) 11.9% 16.3% 2019PF 2022E EBITDA Margins (1) CLARIANT COLOR: TRANSFORMATIONAL ACQUISITION ($ in millions) (1) Financial information is pro forma to include a full year of Clariant Color business SUNBELT PVC Resins DSS 20 Acquisitions $4.8B Investment $2.7B of Annual Revenue 5 Divestments $2.3B Proceeds TPE PP&S HISTORIC SPECIALIZATION THROUGH M&A 13 Distribution DSM Protective Materials BOLT-ON ACQUISITION HISTORY 14 Commercial Resources Operating Income ($ in millions) Operating Margins 259 363 At Acquisition 2022E $40 $139 At Acquisition 2022E 9% 22% At Acquisition 2022E Established Acquisitions (> 7 years) + 40% + 248% + 1300 bps I N V E S T T O G R O W SPECIALTY TRANSFORMATION T O D A Y 7% 46% 67% 86% 100% 0% 20% 40% 60% 80% 100% 2005 2010 2019 2021 2022 PF % o f A d ju st ed E B IT D A • Commodity JVs • Distribution • Performance Products & Solutions • Specialty Businesses (1) Adjusted EBITDA is EBITDA excluding corporate costs and special items (2) Pro forma for the acquisition of Dyneema® and divestiture of Distribution (1 ) (2) 15 Healthcare 4% Packaging 8% Consumer 10% Building & Construction 43% Industrial 15% Transportation 14% Energy 4% Telecom. 2% 2006 2022 Pro Forma Healthcare 8% Packaging 23% Consumer 21% Building & Construction 10% Industrial 15% Transportation 9% Energy 4% Telecom. 4% Defense 6% END MARKET FOCUS ON LESS CYCLICAL INDUSTRIES 16 14.8% 17.6% 21.0% 2018 2020 2022 PF 1.8% 2006 15.3% 16.2% 17.0% 2018PF 2020PF 2022E CAI 2.7% 2006 SEM SPECIALTY EBITDA MARGIN EXPANSION 17 • Portfolio transformation accelerates growth in less cyclical, higher margin end markets • Investments in our composites platform continue to drive margin expansion (1) (1) (1) 2018 and 2020 financial information is pro forma to include a full year of Clariant Color acquisition PORTFOLIO EVOLUTION OVER THE YEARS 18 Adj. EBITDA Margins (1) • Focus on organic growth combined with transformative and bolt-on acquisitions • Divested commodity businesses tied to more cyclical end markets • Expanded presence in high growth areas of sustainable solutions, specialty healthcare applications, composites and more resilient end markets 5.4% 11.5% 16.1% 2006 2018 2022PF $142 $408 $585 2006 2018 2022PF 2006 figures exclude joint venture results 19 RETURNING CASH TO SHAREHOLDERS Growing Dividend 0.1 0.1 0.2 0.5 0.6 0.7 0.8 0.9 0.9 1.0 1.0 1.0 11 12 13 14 15 16 17 18 19 20 21 22 0.16 0.20 0.26 0.34 0.42 0.50 0.58 0.72 0.79 0.81 0.85 0.95 0.99 11 12 13 14 15 16 17 18 19 20 21 22 23 ~$1Bn REPURCHASED OVER LAST 11 YEARS ~$550MM PAID OVER LAST 11 YEARS Dividends Share Repurchases Cumulative Buybacks $B n $ p e r sh ar e $2.95 2022 PRO FORMA ADJUSTED EPS Earnings Growth Expanding Profitability $0.15 $1.09 $2.08 $2.67 $2.95 2009 2012 2015 2018 2022PF T H IR D Q UART ER 2022 RE S U LTS $110 $119 2021 2022 $0.61 $0.59 2021 2022 Q3 2022 PERFORMANCE (TOTAL COMPANY CONT. OPS) 21 Sales Adjusted EBITDA $818 $823 2021 2022 + 1% Adjusted EPS + 8% - 3% (in millions) (in millions) (+ 9% excluding FX) (+ 18% excluding FX) (+ 5% excluding FX) Q3 EBITDA BRIDGE (PRO FORMA TOTAL COMPANY) 22 Price increases more than offset raw material and supply chain impacts $ millions CAI: 68Price / Mix (44)Inflation SEM: 41Price / Mix (26)Inflation 39Net Price Benefit (14)Wage and Energy Inflation 6Clariant Color Integration Synergies 14Incentives, Other Employee Costs (11)FX $137 Q3 2022   Adjusted EBITDA $ 142Q3 2021 (39)Demand Q3 2022 SEGMENT PERFORMANCE 23 CAI $587 $566 Sales ($ in millions) $93 $93 EBITDA SEM Pro Forma $326 $319 Sales $70 $62 EBITDA (+ 4% excluding FX) - 4% - 2% (+ 5% excluding FX) Flat (+ 7% excluding FX) - 11% (- 7% excluding FX) $500 $585 Cont.

July 19, 2017 July 19, 2017 Factors that could cause actual results to differ materially from those implied by these forward-looking statements include, but are not limited to: our ability to realize anticipated savings and operational benefits from the realignment of assets, including the closure of manufacturing facilities; the timing of closings and shifts of production to new facilities related to asset realignments and any unforeseen loss of customers and/or disruptions of service or quality caused by such closings and/or production shifts; separation and severance amounts that differ from original estimates; amounts for non-cash charges related to asset write-offs and accelerated depreciation realignments of property, plant and equipment that differ from original estimates; our ability to identify and evaluate acquisition targets and consummate acquisitions; the ability to successfully integrate acquired businesses into our operations, such as

This is particularly evident in the expanding market of point-of-care testing (POCT) where diagnostic devices such as blood monitoring systems and test kits for infectious diseases and viruses (flu, COVID-19, HIV) are becoming more accessible to the public. COVID-19 Containment Tube Screw Caps Caps and Closures

Premium Spirits Closures - Case Study (Spanish) Distinguished Gravi-Tech™ high-density closures are focused on luxury perception as showcased in the spirits industry Premium Spirits Closures - Case Study (English)

FDA/EU compliance information available upon request Mevopur™ Healthcare Colorants and Formulations for Ophthalmic Closures The Mevopur™ range of standard concentrates for closures used with ocular (ophthalmic) medicines matches the color standards from the American Academy of Ophthalmology (AAO). KEY CHARACTERISTICS • Manufactured at four ISO 13485 certified manufacturing sites, providing global consistency and increased security of supply • Documented change control beyond CAS number, reducing risk of change • Non-phthalate and formulated without animal- derived substances • Standard concentrates in a PE carrier and on request in PP • Pre-colored formulations can be supplied in specific resins selected for the application REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 and USP biological evaluation - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities • Registered Drug Master File (Type III) • Food contact established with FDA/EU* APPLICATION BULLETIN DRUG TYPE COLOR DESCRIPTION PANTONE REFERENCE AVIENT PRODUCT CODE PE BASED Adrenergic agonist combinations Light Green 373 C PE6M176349 Adrenergic agonists Purple 2583 C PE4M176057 Anti-infectives Tan 467 C PE8M176130 Anti-inflammatory, nonsteroidal Grey Cool Grey 4 C PE7M176184 Anti-inflammatory, steroids Pink 197 C PE3M176237 Anti-inflammatory, immunomodulators Olive Green 5763 C On request Beta-blockers Yellow Yellow C PE1M176160 Beta-blocker combinations Dark Blue 281 C PE5M176272 Carbonic anhydrase inhibitors Orange 1585 C PE2M176089 Cytotoxic Black 6 C PL9M176008 Miotics Dark Green 348 C PE6M176267 Mydriatics and cycloplegics Red 1797 C PE3M176236 Prostaglandin analogues Turquoise 326 C PE5M176273 Healthcare use limitations apply—see below.

Both parts are made of silica/glass or polymer 4. Binder • PET, Polyester, Kevlar yarns coated with Swellcoat (absorbs and blocks water) 2 3 4 5 7 6 8 9. Cable jacket/sheath– Made of PE or PVC 9 Fiber-Line Product PolyOne Materials F I B E R O P T I C A L G R O W T H D R I V E R S PolyOne Corporation 22 5G Networks  Enable lower latency, greater flexibility & efficiency  Installation of these networks are in the very early stages  Installation will start in urban hubs and will continue to expand into suburban and rural areas  By 2025, only 14% of the world will have 5G connections  Growth is expected over multi- year period 5G technology will be a leading growth driver in fiber optic cable for several years 10x Speed Increase & 8x More Antennae Required 5G vs. 4G PolyOne Corporation 23 Safety Technology Geography Service FinancialPeople Low EH&S risk profile New and complementary technologies Leverage our global footprint Strong customer relationships Foundational operating margins of 8-10% with ability to double Motivated team with a specialty culture I N V E S T - T O - G R O W M & A S T R A T E G Y PolyOne Corporation 24 Capture sourcing synergies Cross-sell & blend technology 8-10% operating margins I N V E S T - T O - G R O W M & A P L A Y B O O K Protect customers Retain employees Implement LSS to drive efficiency improvements Innovate with combined portfolio Safety First!

The typical width of this gate is 1–4 times the wall thickness. Gate Freeze Time = 4 seconds, 4+1 = 5, Hold Time = 5 seconds • Figure 45 shows an example of the gate freeze study. Print. 4.

Microsoft Word - Avient Announces Fourth Quarter and Full Year 2024 Results 1 NEWS RELEASE FOR IMMEDIATE RELEASE Avient Announces Fourth Quarter and Full Year 2024 Results • Fourth quarter sales increased 4% to $747 million and full year sales increased 3% to $3,240 million • Organic sales, which excludes the impact of foreign exchange, grew 5% and 4% in the fourth quarter and full year, respectively, driven by positive growth in all regions • Fourth quarter and full year GAAP EPS from continuing operations of $0.52 and $1.84 compared to $0.30 and $0.83 in the prior year • Fourth quarter adjusted EPS of $0.49, above mid-point of guidance range of $0.46 to $0.50 and includes a $0.01 unfavorable impact from foreign exchange • 2024 full year adjusted EPS of $2.66 represents an increase of 13% over the prior year, driven by sales growth and margin expansion in both segments • 2025 full year adjusted EPS expected to range from $2.70 to $2.94; the mid-point represents 11% growth when excluding the unfavorable impact of foreign exchange of $0.12 CLEVELAND – February 13, 2025 – Avient Corporation (NYSE: AVNT), an innovator of materials solutions, today announced its fourth quarter and full year results for 2024. As we begin 2025, we are poised to execute our strategy to deliver value for our shareholders by prioritizing our portfolio, amplifying innovation, leveraging digital technologies and harnessing the collective strengths of our more than 9,000 global employees.” Eastern Time on February 13, 2025.

MEVOPUR Colors for Ophthalmic Closures Application Bulletin_CN8.18-1 * 可根据要求提供FDA/EU合规信息 应用公告 用于眼科药物容器盖的 着色剂MEVOPUR™ 用于眼部（眼科）用药物容器盖的MEVOPUR标 准母粒系列产品符合美国眼科学会（AAO）的颜 色标准。 法规支持 经过预测试的原材料： - ISO 10993-1 - USP 第、章（VI类） - USP （指南），6.2.3 可萃取元素； USP - ICHQ3D/USP 2 可萃取金属 - 欧洲药典 3.1 聚烯烃（如适用） FDA发布的注册药品管理档案（III类）和/或医 疗器械管理档案 食品接触符合FDA/EU*要求 • • • 主要特性 在三个通过ISO 13485认证的医疗生产线生产 全球统一的配方，提供全球一致性和供应链保 障 变更控制记录的不限于CAS编号级别，降低变 更风险 不含动物源性物质和邻苯二甲酸盐 标准母粒在PE载体中提供，可根据要求在PP 中提供 可以采用针对应用选择的特定树脂提供预着色 配方 • • • • • 药物类型 颜色说明 潘通色号参考 埃万特产品代码 （PE基） 肾上腺素能激动剂组合 浅绿色 373 C PE6M176349 肾上腺素能激动剂 紫色 2583 C PE4M176057 抗感染药 棕褐色 467 C PE8M176130 非甾体类抗炎药 灰色 冷灰色 4 C PE7M176184 甾体类抗炎药 粉色 197 C PE3M176237 免疫调节剂类抗炎药 橄榄绿 5763 C 按要求提供 β-受体阻滞剂 黄色 黄色 C PE1M176160 β-受体阻滞剂组合 深蓝色 281 C PE5M176272 碳酸酐酶抑制剂 橘黄色 1585 C PE2M176089 细胞毒素 黑色 6 C PL9M176008 缩瞳剂 深绿色 348 C PE6M176267 散瞳剂和睫状肌麻痹剂 红色 1797 C PE3M176236 前列腺素类似物 绿松石 326 C PE5M176273 适用医疗保健使用限制—见下文。 在不限制本声明的一般性的情况下，不得将埃万特的产品用于旨在用于以下目的的任何医疗器械应用： (1) 接触人体组织或体液长达30天或更长时间； (2)“整形”（整容或重建）手术； (3) 生殖植入物或任何节育器械；或者 (4) 用于支持或维持人类生命的永久性（超过30天）植入式医疗器械中的任何关键组件。